18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms
Not yet recruiting
- Conditions
- Neuroendocrine Tumors
- Registration Number
- NCT07102056
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Brief Summary
The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 152
Inclusion Criteria
- Clinical diagnosed of neuroendocrine neoplasms.
- Suspected of neuroendocrine neoplasms.
Exclusion Criteria
- Inability to undergo biopsy/surgical treatment.
- Concurrent active malignancy.
- Severe uncontrolled comorbidities/active infections.
- Inability to provide informed consent.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnostic efficacy through study completion, an average of 1.5 year Sensitivity, specificity, positive and negative predictive value of 18F-OC PET/CT and PET/MR Imaging in neuroendocrine neoplasms
- Secondary Outcome Measures
Name Time Method